MXPA06000507A - Pyrazolines as par-1 antagonists for treatment of cardiovascular diseases. - Google Patents

Pyrazolines as par-1 antagonists for treatment of cardiovascular diseases.

Info

Publication number
MXPA06000507A
MXPA06000507A MXPA06000507A MXPA06000507A MXPA06000507A MX PA06000507 A MXPA06000507 A MX PA06000507A MX PA06000507 A MXPA06000507 A MX PA06000507A MX PA06000507 A MXPA06000507 A MX PA06000507A MX PA06000507 A MXPA06000507 A MX PA06000507A
Authority
MX
Mexico
Prior art keywords
pyrazolines
treatment
par
antagonists
cardiovascular diseases
Prior art date
Application number
MXPA06000507A
Other languages
Spanish (es)
Inventor
Mark Jean Gnoth
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004010545A external-priority patent/DE102004010545A1/en
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of MXPA06000507A publication Critical patent/MXPA06000507A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

The invention relates to pyrazolines of formula (I), where E = methylene, NH, O or S and R2 = a group of formula (II), methods for the production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases, in particular, cardiovascular diseases, such as thromboembolitic diseases.
MXPA06000507A 2003-07-15 2004-07-02 Pyrazolines as par-1 antagonists for treatment of cardiovascular diseases. MXPA06000507A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10331951 2003-07-15
DE102004010545A DE102004010545A1 (en) 2003-07-15 2004-03-04 pyrazolines
PCT/EP2004/007227 WO2005007157A1 (en) 2003-07-15 2004-07-02 Pyrazolines as par-1 antagonists for treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
MXPA06000507A true MXPA06000507A (en) 2006-04-05

Family

ID=34081645

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06000507A MXPA06000507A (en) 2003-07-15 2004-07-02 Pyrazolines as par-1 antagonists for treatment of cardiovascular diseases.

Country Status (8)

Country Link
EP (1) EP1648447A1 (en)
AU (1) AU2004257406A1 (en)
BR (1) BRPI0412554A (en)
CA (1) CA2532316A1 (en)
MA (1) MA27905A1 (en)
MX (1) MXPA06000507A (en)
NO (1) NO20060733L (en)
WO (1) WO2005007157A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004061748A1 (en) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Azetidine-substituted pyrazolines
DE102004061747A1 (en) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Thiophene-substituted pyrazolines
DE102004061751A1 (en) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Cyanoguanidine-substituted pyrazolines
ES2722431T3 (en) * 2014-12-08 2019-08-12 Bayer Pharma AG Novel aryl cyanoguanidine compounds
EP3283480A1 (en) 2015-04-17 2018-02-21 Bayer Pharma Aktiengesellschaft Novel aryl-cyanoguanidine compounds
US20180118722A1 (en) * 2015-04-17 2018-05-03 Bayer Pharma Aktiengesellschaft Novel aryl-cyanoguanidine compounds
EP3109237A1 (en) 2015-06-22 2016-12-28 AnaMar AB Novel 5-ht2 antagonists
CN111892585A (en) * 2020-08-05 2020-11-06 杭州维坦医药科技有限公司 N-formamido pyrazoline derivative as P2X3 receptor antagonist and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE188690T1 (en) * 1990-07-13 2000-01-15 Rohm & Haas N-ARYL-3-ARYL-4-SUBSTITUTED-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE AND METHOD FOR THE PRODUCTION THEREOF
DE4217862A1 (en) * 1991-08-28 1993-03-04 Bayer Ag SUBSTITUTED PYRAZOLINE
DE4217863A1 (en) * 1991-08-28 1993-03-04 Bayer Ag SUBSTITUTED PYRAZOLINE
DE4217864A1 (en) * 1992-05-29 1993-12-02 Bayer Ag Substituted pyrazolines
DE4233713A1 (en) * 1992-10-07 1994-04-14 Bayer Ag Substituted 4,5-dihydro-1-pyrazolecarboxanilides

Also Published As

Publication number Publication date
AU2004257406A1 (en) 2005-01-27
EP1648447A1 (en) 2006-04-26
MA27905A1 (en) 2006-05-02
NO20060733L (en) 2006-04-10
WO2005007157A1 (en) 2005-01-27
CA2532316A1 (en) 2005-01-27
BRPI0412554A (en) 2006-09-19

Similar Documents

Publication Publication Date Title
NL300933I2 (en) Letermovir
MX2007000505A (en) Substituted oxindol derivatives and medicaments containing the same.
GB0625648D0 (en) Compounds
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
MX2007002470A (en) Substituted phenylaminothiazoles and use thereof.
GEP20125565B (en) Lactam compounds and their pharmaceutical use
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
TNSN07272A1 (en) Substituted bis aryl and heteroaryl compounds as selective 5ht 2a antagonists
TW200510416A (en) P38 inhibitors and methods of use thereof
IN2005DE03350A (en)
MX2007000224A (en) Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines in the treatment of nausea and vomiting.
TW200503710A (en) Novel compounds
RS20050070A (en) Use of 1kb kinase inhibitors for the treatment of pain
ATE433966T1 (en) METHYLENE DIPPERIDINE DERIVATIVES
TW200700064A (en) Novel compounds
UA85707C2 (en) Benzoxazines for treating respiratory tract diseases
MX2007006754A (en) Indenyl derivatives and use thereof for the treatment of neurological disorders.
TW200634013A (en) Quinoline derivative, its use, production and pharmaceutical agents containing the derivative
PL1620425T3 (en) Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
WO2003106450A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
UA86399C2 (en) Normal;heading 1;heading 2;USE OF 2,5-DIHYDROXYBENZENESULPHONIC ACID IN THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF ANGIODEPENDENT DISEASES
TW200726763A (en) Novel compound
TW200514781A (en) Novel compounds
NO20060733L (en) Pyrazolines as PAR-1 antagonists for the treatment of cardiovascular diseases
MY146802A (en) Novel drugs for treating respiratory diseases